# A Study of RAY1225 in Participants With Impaired Kidney Function

> **NCT06613763** · PHASE1 · COMPLETED · sponsor: **Guangdong Raynovent Biotech Co., Ltd** · enrollment: 32 (actual)

## Conditions studied

- Kidney Impairment

## Interventions

- **DRUG:** RAY1225

## Key facts

- **NCT ID:** NCT06613763
- **Lead sponsor:** Guangdong Raynovent Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-11
- **Primary completion:** 2025-01-10
- **Final completion:** 2025-01-20
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06613763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06613763, "A Study of RAY1225 in Participants With Impaired Kidney Function". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06613763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*